Colorectal Cancer Market Size to Accelerate at a Rapid CAGR of 3.3% by 2028

Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the global colorectal cancer market growth. However, pricing pressure on drug manufacturers is hindering the market growth. Colorectal cancer is a malignant tumor of the large intestine's inner wall. This is due to abnormal cell growth that can invade or spread to other body parts. Colorectal cancer is commonly caused by inflammatory bowel disease and genetic inheritance. Fatigue, diarrhea or constipation, shortness of breath, weakness, change in bowel habits, red or dark blood in stool, weight loss, abdominal pain, and bloating are a few common symptoms. Colorectal cancer is classified into four stages: stage 0, stage I-cancer in the inner layers of the colon, stage II-cancer spreads through the muscle wall of the colon, stage III-cancer spreads to lymph nodes, and stage IV-cancer spreads to other organs. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.

Click to GET PDF Copy at - https://www.theinsightpartners.com/sample/TIPRE00006881/?utm_source=OpenPR&utm_medium=10723

The List of Companies-

- Amgen Inc.
- Bruker Corporation
- Epigenomics AG
- Clinical Genomics Technologies Pty Ltd.
- VolitionRx Limited
- Novigenix SA
- F. Hoffmann-La Roche AG
- Abbott
- EDP Biotech
- Quest Diagnostics   

Segments-

Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. The diagnosis type segment accounted for the largest share of the market in 2022. Further, it is anticipated to register a higher CAGR during the forecast period, owing to an increasing number of diagnostics tests done by patients. The diagnosis type segment is further categorized into immunochemistry, stool test, flexible sigmoidoscopy, colonoscopy, CEA test, and others. Leading companies offer a huge range of products; for instance, Roche offers robust tools to aid in colorectal cancer diagnostics; the portfolio of assays includes VENTANA MLH-1 (M1) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Antibody, and VENTANA CDX-2 (EPR2764Y).

Speak to Our Analyst at - https://www.theinsightpartners.com/speak-to-analyst/TIPRE00006881/?utm_source=OpenPR&utm_medium=10723

Our reports will help clients solve the following issues: -

> Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

> Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

> Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

> Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Order a copy of this research study at - https://www.theinsightpartners.com/buy/TIPRE00006881/?utm_source=OpenPR&utm_medium=10723

Colorectal Cancer Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.